Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Modern treatment approaches offer numerous options ... Acupuncture shows promise in reducing overactive bladder symptoms and stress incontinence. However, results vary among individuals, and more ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

An overactive bladder may be temporary or become a chronic condition. How long the symptoms last may depend on factors like the underlying cause and treatment adherence. Some conditions may cause ...

Urination problems affect millions of men worldwide, often developing so gradually that many dismiss early warning signs.

The goal of this assessment will be to focus on the role of PTNS in the treatment of overactive bladder.

Gemtesa is approved for men with overactive bladder symptoms who are receiving pharmacologic treatment for benign prostatic hyperplasia.

Depositphotos *We spoke to actress, advocate, and philanthropist Holly Robinson Peete about her current projects and her journey with overactive ... information on treatment options, such as ...

The researchers concluded clinicians need to "take into account the possible long term risks and consequences of the available treatment options for an overactive bladder in older adults".